ReviewAnnals of intensive care2026
Remote ischemic conditioning in intensive care: From bench to bedside.
Review in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia/reperfusion (I/R) injury is a pathological phenomenon involving temporary blood flow restriction (ischemia) followed by a period of reperfusion. This sudden variation induces oxidative stress, inflammation, and mitochondrial dysfunction, leading to severe cellular damage. I/R is a primary driver of organ injury in critically ill patients, particularly in conditions such as myocardial infarction, stroke, cardiac arrest, trauma, cardiac surgery, and various shock states. Remote ischemic conditioning (RIC), a non-invasive strategy involving repeated controlled episodes of ischemia and reperfusion to a distant organ (typically a limb), has emerged as a potential strategy to attenuate I/R injury through systemic protective mechanisms. RIC can be applied at various time points: i) before ischemia (pre-conditioning); ii) during ischemia (per-conditioning); iii) after reperfusion has started (post-conditioning). While preclinical models have consistently demonstrated its efficacy, clinical trials to date have shown mixed results, with limited impact on key clinical outcomes. In this narrative review, we first provide a brief historical overview and outline the molecular and cellular mechanisms underlying RIC. Second, we examine current evidence from both animal studies and human trials on the effect of RIC across several conditions such as myocardial infarction, stroke, cardiac arrest, trauma, cardiac surgery and shock. Finally, we discuss ongoing research efforts aimed at optimizing its delivery and identifying patient populations most likely to benefit from its use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.